Stephens Consulting, LLC Recursion Pharmaceuticals, Inc. Transaction History
Stephens Consulting, LLC
- $422 Billion
- Q2 2025
A detailed history of Stephens Consulting, LLC transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Stephens Consulting, LLC holds 67 shares of RXRX stock, worth $362. This represents 0.0% of its overall portfolio holdings.
Number of Shares
67
Previous 187
64.17%
Holding current value
$362
Previous $990,000
65.66%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding RXRX
# of Institutions
359Shares Held
283MCall Options Held
3.29MPut Options Held
3.24M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl33MShares$178 Million1.38% of portfolio
-
Vanguard Group Inc Valley Forge, PA32.3MShares$175 Million0.0% of portfolio
-
Baillie Gifford & CO24.2MShares$131 Million0.1% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$93.6 Million0.0% of portfolio
-
Softbank Group Corp Minato Ku Tokyo, M014.7MShares$79.4 Million0.27% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $976M
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...